Rare Disease Drug Approvals Accelerate as FDA Clears Three New Orphan Therapies
May 2026 — The U.S. Food and Drug Administration has approved three therapies in May…
𝗙𝗗𝗔’𝘀 𝗘𝘃𝗼𝗹𝘃𝗶𝗻𝗴 𝗦𝘁𝗮𝗻𝗰𝗲 𝗼𝗻 𝗕𝗮𝘆𝗲𝘀𝗶𝗮𝗻 𝗠𝗲𝘁𝗵𝗼𝗱𝘀: 𝗪𝗵𝗮𝘁 𝗦𝗽𝗼𝗻𝘀𝗼𝗿𝘀 𝗡𝗲𝗲𝗱 𝘁𝗼 𝗞𝗻𝗼𝘄 𝗶𝗻 𝟮𝟬𝟮𝟲
What we see at the January 2026 draft guidance, which formalizes a major shift: Bayesian…
New Age of Biological Research That Changed The Last Decade
Digital Twins And The Rise Of One-Trial Rare Disease Development In 2026 Rare disease development…
𝗙𝗮𝗰𝘁𝗼𝗿𝘀 𝗙𝗮𝘃𝗼𝗿𝗶𝗻𝗴 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗔𝗰𝗰𝗲𝗽𝘁𝗮𝗻𝗰𝗲…
• Large, unambiguous treatment effects: In nearly all approved cases (Zolgensma, Kebilidi, Casgevy), the treatment…
End of content
End of content